This study evaluated the survival outcomes after lumpectomy followed by radiation versus mastectomy alone in patients with early-stage HER2-positive (HER2+) breast cancer (BC) and triple-negative breast cancer (TNBC) with low or high tumor-infiltrating lymphocytes (TILs). The data showed that lumpectomy followed by radiation improves survival in patients with high TILs.

This study looked at the use of olaparib (Lynparza) treatment for patients with high risk, BRCA1/2-positive, HER2-negative breast cancer (BC). The authors found that in patients with BRCA1/2-positive BC, olaparib after local treatment improved the outcomes of these patients.

This study investigated the duration, level, and predictors of unacceptable pain during the early stages of rheumatoid arthritis (RA), with and without low inflammation. The authors concluded that over a 5-year period, more than one-third of patients studied had unacceptable pain that was linked to lower swollen joints.

This study investigated whether switching a first-line targeted therapy (TT) within 6 months of not attaining low disease activity (LDA) enhances the chance of patients with rheumatoid arthritis (RA) achieving their target at the 12-month visit. The data showed an increased chance of achieving a target of remission or LDA at the 12-month visit with a TT switch within 6 months.

This study aimed to investigate depression and cognitive (thinking and reasoning) functions after taxane-based chemotherapy in patients with breast cancer. 

This study concluded taxane-based chemotherapy commonly leads to cognitive impairment in these patients, but some functions improve or remain stable after stopping treatment.

This study was carried out to examine the impact of physical activity (PA) on the recovery of patients having surgery for breast cancer (BC). The authors found that PA reduces the risk of patients developing chronic pain and women who had higher levels of PA recovered better than sedentary women. 

This study investigated the relationship between tumor necrosis factor-alpha (TNFα), interleukin (IL)-6, and serum certolizumab pegol (CZP; Cimzia) levels in patients with rheumatoid arthritis (RA) treated with CZP. The authors concluded that CZP was highly effective in patients with low serum TNFα levels at 24 hours after the first dose.

This study analyzed the effect of using biological disease-modifying anti-rheumatic drugs (bDMARDs) on fracture risk in patients with rheumatoid arthritis (RA). The data suggest no evidence that the use of bDMARDs impacts fracture risk in these patients.

This study described the guidelines from the Canadian Rheumatology Association (CRA) on the use of COVID-19 vaccines in patients with autoimmune rheumatic diseases (ARDs). The CRA recommended the use of Canada-approved COVID-19 vaccines for patients with ARDs.

This study evaluated the association between patient-reported outcomes (PROs) and survival outcomes in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC) treated with abemaciclib (Verzenio). The data showed that the PROs could be a predictor of survival benefits in these patients.